On Wednesday, Shares of Intel Corporation (NASDAQ:INTC), gained 0.13% to $29.69.
Intel Corporation, said Wednesday that greater demand from data centers and sales of memory products assisted counteract the slumping PC market in the second quarter, according to AP.
The world’s largest chipmaker said its net income and revenue both fell contrast to last year and it again trimmed its estimates for the year, but the results looked good contrast to Wall Street’s estimates. Shares of Intel Corp. rose 69 cents, or 2.3 percent, to $30.38 in aftermarket trading. AP Reports.
Intel said its profit fell 3 percent to $2.71 billion, or 55 cents per share, and revenue shrank 5 percent to $13.2 billion. AP added.
Intel Corporation designs, manufactures, and sells integrated digital technology platforms worldwide. It operates through PC Client Group, Data Center Group, Internet of Things Group, Mobile and Communications Group, Software and Services, and All Other segments.
Shares of Johnson & Johnson (NYSE:JNJ), inclined 0.64% to $100.42, during its last trading session.
Johnson & Johnson, declared sales of $17.8 billion for the second quarter of 2015, a decrease of 8.8% as contrast to the second quarter of 2014. Operational results reduced 0.9% and the negative impact of currency was 7.9%. Domestic sales reduced 2.4%. International sales reduced 14.3%, reflecting operational growth of 0.5% and a negative currency impact of 14.8%. Not taking into account the net impact of acquisitions and divestitures, on an operational basis, worldwide sales raised 1.7%, domestic sales raised 0.6% and international sales raised 2.7%. Additionally not taking into account hepatitis C sales, underlying operational growth worldwide was 5%.
Net earnings and diluted earnings per share for the second quarter of 2015 were $4.5 billion and $1.61, respectively. Second quarter 2015 net earnings comprised of after-tax intangible amortization expense of about $0.2 billion and a charge for after-tax special items of about $0.1 billion. Second quarter 2014 net earnings comprised of after-tax intangible amortization expense of about $0.4 billion and a charge for after-tax special items of about $0.4 billion. A reconciliation of non-GAAP financial measures is comprised of as an accompanying plan. Not taking into account after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $4.8 billion and adjusted diluted earnings per share were $1.71, representing decreases of 6.3% and 3.9%, respectively, as contrast to the same period in 2014. On an operational basis, adjusted diluted earnings per share raised 6.7%.
Johnson & Johnson, together with its auxiliaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices.
Finally, Opko Health, Inc. (NYSE:OPK), ended its last trade with -0.66% loss, and closed at $16.63.
OPKO Health, has accomplished enrollment in the single pivotal Phase 3 trial of its long acting human growth hormone (hGH-CTP) in growth hormone deficient (GHD) adults.
The trial is designed to evaluate the safety and efficacy of hGH-CTP with a primary endpoint of superiority contrast to placebo in decreasing fat mass in adults with GHD. The trial is a randomized, double-blind, placebo-controlled, multi-center, global study in adults with GHD. The study is divided into two treatment periods: a 26-week, double-blind, placebo-controlled period, followed by a 26-week, open-label extension.
The study is predictable to end toward the second half of 2016; regulatory submission will follow study completion.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
